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We have come a long way since the first EPI-AID was conducted in 
1946. Reflecting the mission of the then Communicable Disease Center, the 
first EPI-AIDs were epidemiologic investigations of acute infectious disease 
outbreaks. Today, states and the Centers for Disease Control and Prevention 
(CDC) address an ever-expanding range of health problems, such as birth 
defects, cancer and other chronic diseases, maternal and child health, 
injuries, smoking, and environmental health threats, and today’s EPI-AIDs 
reflect these priorities. Although the majority of EPI-AIDs are still to 
investigate acute infectious disease outbreaks, an increasing number involve 
non-infectious diseases and occupational or environmental health concerns.
Participation in an EPI-AID represents an exciting opportunity to 
obtain first-hand experience in solving many of today’s new and complex 
public health problems. At the same time, it helps to fulfill one of CDC’s 
most important functions—that of assisting states with the attainment of 
their health priorities. Thus, the EPI-AID is the most visible and dramatic 
mechanism by which CDC fulfills its mission as the Nation’s prevention 
agency.
This Guidelines document is provided to all CDC personnel involved 
with EPI-AIDs so that the rationale, mechanics, and processing of EPI-AIDs 
can be better understood and handled. Our ultimate goal is to facilitate the 
most important part of the entire process—the actual epidemiologic field 
investigation.
Willard Cates, Jr., M.D., M.P.H. 
Director, Division of Training 
Epidemiology Program Office
110642
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I. Introduction and Purpose
The Centers for Disease Control and Prevention (CDC) has gained national and worldwide recognition for its rapid and 
effective investigations of health emergencies. Speedy assessment of 
adverse health events and rapid application of prevention and 
control measures are fundamental to the overall mission of CDC. 
This is one of the most important ways in which CDC serves to 
protect the health of the American people.
Because of the difficulty in dealing with the complex and 
immediate demands created by epidemics and disaster situations, 
states and foreign nations frequently look to CDC for short-term 
epidemiologic assistance. CDC has unique epidemiologic expertise 
in a variety of diseases and conditions, including the investigation 
of rare conditions and unknown agents. When assistance is 
requested, CDC makes every effort to respond by dispatching 
epidemiologic investigators, supported when necessary by 
specialists in other areas (sanitarians, ventilation engineers, etc.) to 
participate in epidemiologic field investigations. During these 
investigations, CDC staff act as consultants to a state (and 
sometimes local) health department or the health ministry of the 
host nation, investigating the patterns of disease or injury 
occurrence, the levels of risk behaviors, the identity of the etiologic 
agent, the transmission of the condition of concern, and the impact 
of preventive interventions. The goal is for prevention and control 
measures to be rapidly instituted.
Within CDC, a formal request for epidemiologic assistance from a 
state or international health agency is frequently referred to as a 
request for “EPI-AID” assistance. The term, EPI-AID, denotes that a 
specific administrative mechanism has been invoked to support the 
field response. Since this mechanism was first used in 1946, over 
3,000 EPI-AIDs have been performed.
In 1981, the Epidemiology Program Office (EPO) was established 
and given primary responsibility for administering and managing 
EPI-AIDs. In 1991, EPO formed the Division of Training (DT) to 
better coordinate training in applied epidemiology throughout 
CDC. Since EPI-AID investigations provide unique training 
opportunities in the science and practice of epidemiology, 
especially for Epidemic Intelligence Service (EIS) officers, the 
responsibility for administering and managing EPI-AIDs now rests 
with EPO’s Division of Training.
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The purpose of this document is to acquaint CDC personnel with 
current policies, guidelines, and procedures related to the EPI-AID 
process. It reflects changes and revisions since the last issuance of 
Guidelines for Reporting Epidemiologic Investigations (EPI-AIDS) in 
1990. Specifically, this document covers the policies and guidelines 
governing the use of the EPI-AID mechanism and the 
administrative procedures to follow when responding to requests 
for epidemiologic assistance, notifying appropriate officials, and 
conducting and reporting the EPI-AID investigation.
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II. Overview
The EPI-AID mechanism is a means by which EIS officers and other CDC staff can provide technical support to requesting 
organizations for epidemiologic field investigations. This 
mechanism allows CDC to (1) respond rapidly to public health 
problems in need of urgent attention, thereby providing an 
important service to state and other public health agencies; and
(2) provide supervised training opportunities for EIS officers (and, 
sometimes, other CDC staff) to actively participate in epidemiologic 
investigations.
The EPI-AID mechanism may be defined operationally as an 
administrative method that is used to facilitate epidemiologic field 
investigations by EIS officers, Preventive Medicine Residents 
(PMRs), and other CDC staff when the conditions detailed below 
exist:
■ Epidemiologic assistance has been requested by appropriate 
officials of a state, international health agency, or foreign 
government;
■ The request involves a problem of public health importance;
■ Timely response is required;
■ Epidemiologic methods are primarily required;
■ An investigation would contribute to the professional 
development of an EIS officer/PM R in practical epidemiology;
■ O ther sources of support are not available; and
■ The response is not part of previously planned or ongoing 
activities being undertaken by the relevant CDC program.
In operational terms, all CDC responses to requests for 
epidemiologic assistance involving (1) a field investigation of an 
urgent health problem, and (2) one or more EIS officers should be 
considered EPI-AIDS. Important exceptions to the above are the 
National Institute for Occupational Safety and Health (NIOSH) 
Health Hazard Evaluation (HHE) and the field epidemiologic 
investigations performed by state-based officers from EPO’s 
Division of Field Epidemiology (DFE). These investigations and the 
subsequent reporting requirements* serve the same training 
purposes for EIS officers assigned to NIOSH and DFE as EPI-AIDs 
for EIS officers assigned elsewhere.
*  Guidance on documenting these investigations is contained in the Hazard 
Evaluations Procedures M anual [draft] and the Division of Field Epidemiology Field 
Officer Handbook, respectively.
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The Division of Training, EPO, is responsible for managing funds 
related to supporting EPI-AID investigations. The funds available 
each fiscal year for EPI-AIDs are limited within the overall CDC 
budget. Therefore, EPI-AID resources are not a bottomless pit!
The general guideline for the use of EPI-AID funds is as follows:
EPI-AID funds are used to support travel and per diem of 
epidemiologic investigators for a period of up to three weeks 
(four weeks for international investigations). The primary 
purpose is to support travel costs of EIS officers, PMRs, and 
medical students participating in CDC’s Student Elective 
Program, not CDC permanent epidemiologic staff.
As noted above, EPI-AID funds are generally intended to support 
only travel costs associated with an EPI-AID investigation. In 
exceptional circumstances, these funds can be used for other 
expenses (e.g., medical supplies and laboratory expenses), but 
support for costs other than travel must be approved in advance by 
the Division of Training, EPO. Unauthorized investigation-related 
expenses will be assumed by the program with lead responsibility 
for the investigation, and personal expenses will be the 
responsibility of the individual investigator.
Circumstances under which EPI-AID funds may be used to support 
additional travellers and expenses other than travel may vary from 
time to time. Particularly during times of budgetary constraints, 
travel restrictions, etc., interim guidelines may be issued that limit 
the number of investigators and the duration of the investigation.
An investigation fitting the EPI-AID definition may be considered 
an EPI-AID and consequently assigned an EPI-AID number (see 
Section IV), regardless of whether EPI-AID funds are used. 
Non-EPI-AID funds include those from a CDC program or an 
international source. In cases such as these (when an investigation is 
assigned an EPI-AID number but is not supported by EPI-AID 
funds), it is expected that all EPI-AID reporting requirements will 
be fulfilled (see Section VI).
EPI-AID investigations, like all other epidemiologic field 
investigations, are subject to certain policies, approvals, and 
clearances. Most relevant to the conduct of EPI-AID investigations 
are the following:
Human subjects review by an Institutional Review Board (IRB) may 
or may not be required, depending on whether the investigation is 
“research” involving human subjects. It is not always clear when IRB 
review is required according to various written rules and guidelines. 
Nonetheless, it is important that the intent and spirit of the
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regulations on protection of human subjects be followed. EPI-AID 
investigations are generally considered to be a response to a public 
health emergency (rather than research), both to determine the 
cause an d /o r extent of a particular, acute, current health problem 
in a community and also to develop plans for its control. This 
situation is the public health equivalent of an individual 
doctor-patient encounter in which the community as “patient” 
presents with a health problem, and CDC and other health agencies 
as “physician” are expected to diagnose, via the investigation, and 
control (“treat”) without delay.
Nevertheless, situations arise in which the analogy described above 
is less clear. When any doubt exists about the need for IRB review, 
the Human Subjects Review (HSR) contact within the EIS officer’s 
Center/Institute/O ffice (CIO) should be consulted. In those 
instances where IRB review is determined to be necessary and yet 
time is critical (e.g., specimens must be collected within a few days 
or they would be of little use), the HSR contact person can provide 
guidance and take steps to expedite the review process. The guide 
“Protection of the Individual as a Research Subject” (CDC Manual 
Guide No. 11) is also available and includes helpful information on 
the basic elements of informed consent.
A common misconception exists that data collection initiated as a 
result of an EPI-AID does not require clearance by OMB. On the 
contrary, like other investigations performed by the Federal 
government, data collection in an EPI-AID requires official 
clearance by OMB. However, because of the urgent nature of 
EPI-AID investigations and to expedite the EPI-AID process, CDC 
has obtained this clearance in advance provided that the data 
collection does not exceed 30 days. Under this approval, CDC is 
required to document its data collection activities for each EPI-AID 
after the field investigation has occurred. These reporting 
requirements are discussed in Section VI of this document.
Office of Management 
and Budget (OMB) 
Clearance for Data 
Collection












The remainder of this document will cover in greater detail the EPI-AID process, from initiation to completion of an EPI-AID. 
It will describe WHAT steps need to be followed, WHEN they are 
to occur, and WHO is responsible, as depicted below:













/ 1 day 2-3 weeks 1 day 5 days 14 days / /
Domestic
DFE (for state-based 
EISO assistance)
/
Requestor —► CDC Program------------------------►
----------------------O R -------------------------
International
IHPO (for funding 
^  assistance)
Requestor ► CDC Program -----------------*
DT, EPO CDC Program
Figure 1. Schematic of the EPI-AID Process
EPI-AID Investigations 7

IV. Before the EPI-AID Investigation
This section covers the specific procedures to follow for initiating an EPI-AID, obtaining necessary approvals, and preparing for 
the field investigation.
A request for epidemiologic assistance may be initiated by a private 
or public institution or a private individual. The next steps depend 
on whether the health problem originates from a domestic or 
international source.
If the request for assistance is from a domestic source, usually the 
state official (or h is/her designee) with responsibility for the 
particular health problem (generally the state epidemiologist) is 
notified. After determining that epidemiologic assistance is needed, 
the state official offers a formal invitation to CDC, generally to the 
program with primary responsibility for the health problem 
involved. On rare occasions CDC may receive requests for EPI-AID 
assistance directly from other sources, such as the Indian Health 
Service or a Federal penitentiary. In these cases, the CDC program 
must consult with the state epidemiologist and other state officials. 
If the request originates from a state to which an EIS officer is 
assigned, the CDC program must discuss the request with the State 
Branch, Division of Field Epidemiology (DFE), EPO, to determine 
whether the state-based officer is able to provide the necessary 
assistance to the state, perhaps with guidance provided by other 
CDC experts.
If the request for assistance is from an international source, usually 
the CDC program with primary responsibility for the health 
problem involved is contacted. Whenever the possibility of an 
international EPI-AID arises, the CDC program should then inform 
both the Director, Division of Training, EPO, and the Director, 
Division of International Liaison, IHPO, as soon as possible. IHPO 
will provide initial assistance to programs in exploring which of 
several possible sources of financial support may be available. 
Sources of funding that should be considered include the 
government of the host country, WHO or PAHO, USAID, other 
non-CDC federal funding sources, and other CDC sources of funds. 
If alternate funds are unavailable, the CDC program may then 
request assistance through the EPI-AID mechanism.
Once a request is received and the CDC program (and IHPO in 
international cases) determine that CDC assistance is needed, the 
EPI-AID Coordinator should be contacted at 404/639-3182, 
through whom approval will be obtained. During nonbusiness 
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following order: (1) Director, (2) EIS Program Chief, (3) Deputy 
Director. If none of these individuals is available, the Office of the 
Director, EPO, staff should be contacted at home in the following 
order: (1) Assistant Director for Science, (2) Assistant Director,
(3) Deputy Director, (4) Director, (5) Assistant Director for Program 
Operations. Without prior approval from one of these individuals, 
EPI-AID funds will not be available to support the investigation and 
any expenses incurred prior to approval will be the responsibility of 
the program.
Considerations for approval include determining whether an 
EPI-AID is the appropriate mechanism to provide assistance, the 
level of support that EPI-AID funds can provide, the individuals 
involved, supervision, duration of the investigation, etc. In general, 
the following guidelines apply:
■ State-based EIS officers are CDC’s first line of epidemiologic 
assistance in a given state. They and their Atlanta-based DFE 
supervisors should be notified of impending investigations in 
their states. The decision about whether the state-based 
officer will assume primary responsibility or will assist in the 
investigation should evolve after discussions among the 
officer, the local supervisor, the Atlanta-based DFE 
supervisor, and the program that is preparing to respond to 
the EPI-AID. This improves collegiality, facilitates conduct of 
the investigation, and allows for local follow-up of the 
investigation.
■ The number of persons supported by an EPI-AID should be 
appropriate to the size and nature of the investigation. Except 
under unusual circumstances, no more than one EIS officer 
can be supported under this mechanism. However, when 
resources permit, an EIS officer going out on an EPI-AID for 
the first time can be accompanied by a second-year EIS 
officer. If the investigation is in a state that has a second-year 
EIS officer assigned to it, the state-based officer can provide 
the mentoring function.
■ One medical student participating in the Student Elective 
Program may be approved to join in an EPI-AID investigation 
if it will provide a good training experience and the student 
has not participated in a prior EPI-AID.
■ Except in extremely unusual circumstances, EPI-AID funds 
are not available to support CDC (non-EIS, non-PMR) staff 
who accompany EIS officers on EPI-AIDs.
■ The CDC program with expertise in the subject area has 
responsibility for supervising investigators involved in an 
EPI-AID. However, if a state-based officer is involved, the 
CDC program and DFE should discuss and mutually agree on 
supervisory responsibility.
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■ The anticipated duration of support should be verbally agreed 
upon by the Division of Training, EPO, and the relevant CDC 
program when the EPI-AID investigation is initiated. In general, 
EPI-AID investigations are of no more than three weeks’ 
duration (four weeks for international investigations).
■ If needed, extensions of time spent in the field should be 
negotiated and approved in advance. Keeping in mind that OMB 
approval for data collection under the EPI-AID mechanism is 
limited to 30 days, the justification for an extension should be 
scientifically reasonable and related to immediate problems of 
public health importance, not long-term program research 
interests.
■ In general, a single trip should be sufficient to complete an 
EPI-AID. Under extremely unusual circumstances, one follow-up 
trip can be supported by this mechanism, if the program and the 
Division of Training, EPO, consider it necessary for the 
completion of the response to the public health emergency.
International EPI-AIDs have additional requirements for approval. 
Once approved by the Division of Training, EPO, the CDC program 
with lead responsibility for the EPI-AID should inform IHPO of 
who will be investigating the health problem, when the investigator 
plans to depart, etc. IHPO will then be responsible for notifying 
and obtaining necessary approvals from appropriate Health and 
Human Services (HHS), State Department, Agency for 
International Development, and other international agency 
officials. For example, State Department clearance is needed 
whenever government employees travel outside the United States.
When an epidemiologic assistance request is approved as an 
EPI-AID, the CDC program should request a number from the 
EPI-AID Coordinator (404/639-3182). A sequential number is 
assigned to each EPI-AID for purposes of reporting, accountability, 
and tracking. When requesting an EPI-AID number, please be 
prepared to provide the EPI-AID Coordinator with the nature and 
location of the health problem, the principal investigator’s name, 
the officer’s supervisor’s name, date of departure, and expected 
date of return. If the proposed investigation is canceled or 
postponed, please call the EPI-AID Coordinator so that the 
assigned number can be released.
After the Division of Training, EPO, has approved an EPI-AID, 
certain organizational units should be informed as soon as possible 
of the investigation.
The CDC program taking the lead on the EPI-AID is also 
responsible for notifying the appropriate regional office (Director, 
Division of Preventive Health Services). Since this office is 











programs in the region, they must be aware of any CDC 
involvement with potential public health emergencies within their 
jurisdiction.
State governments are responsible for public health in their own 
jurisdictions. At CDC’s request, many states have delegated to the 
state epidemiologist and other state officials the authority to invite 
CDC staff to their state. Most requests for epidemiologic assistance 
are received by CDC from state health officials. In the rare 
instances when a state official did not request epidemiologic 
assistance but an EPI-AID was approved (e.g., a cruise ship 
investigation when state jurisdiction is less clear), the responsible 
CDC program should notify the appropriate state epidemiologist 
and other state officials.
The purpose of the EPI-1 report is to officially inform appropriate 
individuals (CDC Director, CDC professional staff, and state 
epidemiologists) of the suspected health problem. The program 
directing the EPI-AID investigation is responsible for writing the 
EPI-1 report (usually written by the investigating officer or 
supervisor), which should be completed and approved before the 
EPI-AID mission begins. At the time the EPI-1 is prepared, 
responsibility for writing the summary report of the investigation, 
called the EPI-AID Trip Report, should be assigned.
Detailed instructions for preparing the EPI-1 and an example of a 
completed report are contained in Appendix 1.
The EPI-1 report should be short (usually two to three pages), clear, 
factual, and logically organized. It should also follow a prescribed 
format. To facilitate completion, a WordPerfect merge document 
for the EPI-1 has been developed and may be obtained from the 
EPI-AID Coordinator.
The nature of the problem should be brief (one to three sentences). 
Both the seriousness and urgency of the problem should be evident 
from the language chosen. Mention of the history leading up to the 
request or of the request itself is discouraged.
The sources of invitations should always include the state official 
as one of the inviting officials regardless of the initial source of the 
request.
The nature and timing of the response should basically list who 
went out (and when) to assist in the investigation. To reflect the 
state’s an d /o r country’s lead public health responsibility, an EIS 
officer is never sent out to “conduct” or “perform” the 
investigation. Rather, he/she is sent to “assist” or “join in” the 
investigation.
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The objectives of the EPI-AID mission should be presented in 
general terms, such as “to assess the extent of Disease X in the 
population, identify factors influencing risk, and develop 
recommendations for controlling the problem.” A description of 
methods or methodology is not necessary and is generally 
undesirable. (In the real world, study plans often change depending 
on what is found in the field).
For EPI-AIDs with co-investigating officers, the names, titles, and 
organizational affiliations of all participating EIS officers should be 
included. Occasionally, EPI-AID requests involve participation of 
more than one officer and more than one CDC program.
Distribution should list, at a minimum, mailing keys WF-1 (first- 
and second-year EIS officers); WF-2 (EPO professional staff); WF-3 
(CDC professional staff); and ZW (all state epidemiologists). The 
names, titles, and mailing addresses of all other individuals who are 
to receive copies of the EPI-1 should appear below the list of 
mailing keys.
Draft EPI-1 reports are reviewed and approved by the Division of 
Training, EPO. The responsible CDC program should send the 
draft EPI-1 report via E-Mail or FAX to the EPI-AID Coordinator. 
Because of the need to convey the information to public health 
officials, the draft EPI-1 report must be submitted to EPO within 24 
hours of when the EPI-AID number is assigned. The EPI-AID 
Coordinator will notify the or iginating office of any needed 
changes.
After the EPI-1 is approved, the originating office is responsible for 
(1) preparing the EPI-1 in final form; (2) completing a Request for 
Printing Services form (CDC 0.103A); and (3) submitting this 
printing request as soon as possible to the Publications 
Management Section, Management Services Branch, Management 
Analysis and Services Office (MASO), Building 1, Room B122 (see 
Appendix 1). If additional individuals are listed under 
“Distribution” in the EPI-1, the number of additional copies to be 
returned to the program for mailing to these individuals should be 
noted in Item 27 of this form.
MASO will print and mail the EPI-1 to the individuals included in 
mailing keys WF-1,-2,-3, and ZW. The CDC program is responsibile 
for mailing copies to all persons not included on CDC mailing keys.
When EPI-AID funds are used to support the investigation, certain 
procedures should be followed to process the travel order. More 
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When the EPI-AID request is approved during working hours:
■ The EPI-AID Coordinator should be contacted at 
404/639-3182 to obtain a travel order number and the 
appropriate CIO EPI-AID account number.
■ The responsible CDC program should prepare the travel 
order. Unlike other travel prepared by CIOs, however, 
supporting documents for EPI-AID travel must be prepared 
manually. NOTE: Modifications to the CDC computerized 
travel system are now being pilot-tested so that travel 
performed by one CIO can be authorized and paid by 
another CIO. Therefore, in the very near future, CIOs will be 
able to complete EPI-AID travel on-line.
■ For purposes of tracking and accountability, the travel order 
should be sent by FAX to the EPI-AID Coordinator (FAX 
Number 404/639-2222) as soon as it is typed (and before it 
has been approved).
■ The travel order should be reviewed through usual 
administrative channels of the CIO prior to obtaining the 
signature of the authorizing official in the CIO.
■ Once approved, two copies of the signed travel order should 
be sent through interoffice mail to the EPI-AID Coordinator 
(Mailstop C08).
When the EPI-AID is approved during nonbusiness hours and
travel must be initiated immediately, the following steps should be
taken:
■ The airline or other ticket should be purchased with a Diners 
Club credit card, cash, or Government Transportation 
Request (GTR). Every effort should be made to obtain the 
lowest fare possible. Using the Diners Club card will assure 
the government rate for airfare.
■ The government rate for expenses should be requested at all 
times. To obtain these rates, a Public Health Service 
identification card must be shown and should be carried at all 
times.
■ The EPI-AID Coordinator and the appropriate CIO 
Administrative Office should be notified the first workday 
following departure so that a confirmation travel order can be 
issued.
■ Before departure, if an advance of funds is desired, travellers 
are encouraged to use their Diners Club card at the nearest 
automatic teller machine (ATM).
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Many officers have found it useful to review past EPI-AID reports, 
MMWR ariticles, etc., to help prepare for the EPI-AID. The EPI-AID 
Coordinator maintains files on all past EPI-AID reports and can 
assist you in locating relevant documents. In addition, the program 
itself is usually the best source of background information.
Since EPI-AID funds do not generally support materials and 
supplies needed for the investigation, careful consideration should 
be given to such items when packing to avoid purchasing them in 
the field. Moreover, particularly with international EPI-AIDs, 
appropriate supplies and equipment may not be available in some 
countries. Laboratory personnel are excellent resources to help you 
determine relevant supply and equipment needs.
The need for Human Subjects Review should also be evaluated, as 
described in Section II. The issue to consider is whether a 
diagnostic procedure is planned that may be regarded as invasive. 
IRB approval is not necessarily needed for tests that patients get as 
part of their usual care, such as those involving collecting blood or 
other relatively available body fluid.
At the time of preparing for the EPI-AID investigation, 
data-collection instruments are usually being considered. Whenever 
questionnaires or other data-collection instruments are used in an 
EPI-AID, the following statement must be placed on the bottom of 
the first page of the data collection instrument:
Public reporting  burden  o f this collection o f inform ation is 
estim ated to average X (please complete) minutes per response, 
including the tim e for reviewing instructions, search existing 
data sources, gathering and m aintaining the data needed, and 
com pleting and reviewing the collection of inform ation. Send 
com m ents regarding this burden estimate o r any other aspect 
o f this collection o f inform ation, including suggestions for 
reducing this burden  to PHS Reports Clearance Officer, ATTN:
PRA; H ubert H. H um phrey Building, Room 721-B; 200 
Independence Ave., SW; W ashington, DC 20201, and to the 
Office o f M anagement and Budget; Paperwork Reduction 
Project (0920-0008); W ashington, DC 20503.
For an EPI-AID investigation aboard a cruise ship, the Crew Survey 
Questionnaire (Appendix 3) and Passenger Survey Questionnaire 
(Appendix 4) are highly recommended for use in the EPI-AID. 
Additional information on how to proceed in a cruise ship 
investigation may be obtained from the Division of Bacterial and 
Mycotic Diseases, National Center for Infectious Diseases, since this 
Division supervises most cruise ship investigations. Additional 
information may be obtained from the Special Programs Group, 
National Center for Environmental Health; this office is responsible 
for the Vessel Sanitation Program and should be notified about all 
such investigations. Staff from this program frequently join 
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V. During the EPI-AID Investigation
Upon arrival at the investigation site, the investigating officer should contact state an d /o r local officials who requested CDC 
assistance. It is important both to establish rapport with state and 
local health officials and others involved in the outbreak, as well as 
to develop lines of communication and expectations concerning the 
extent and frequency of interaction among the various parties 
involved. At the conclusion of the investigation, the investigating 
officer should conduct an exit briefing with the appropriate 
state/local/m inistry officials. This briefing should both summarize 
the findings of the investigation and detail the recommendations 
for further action.
CDC supervision is established before the EPI-AID investigation 
begins. Except when logistically impossible, the investigating officer 
should call the supervisor daily to discuss investigation progress 
and plans. In the course of the investigation, the supervisor and 
officer may determine that additional time in the field is needed to 
complete the investigation, or that additional costs, such as 
laboratory expenses, are necessary. Any changes from the 
agreements made at the time of original approval must be discussed 
with and approved by the Division of Training, EPO, in advance.
If the points of travel change or an extension of more than two days 
is approved, the travel order will need to be amended (see 
Appendix 2). EPI-AID travel orders contain a standard statement 
“Traveler is authorized variation of itinerary of not more than two 
days at temporary duty point in order to perform official business 
(REFJFTR U2135A).” This statement is included for administrative 
purposes only to avoid preparing a travel amendment when 
extended travel is approved. This statement does not replace the 
requirement to obtain prior approval for extensions of any 
duration, including one- or two-day extensions.
Occasionally, the investigating officer may remain in the field to 
conduct other program business or for personal preference. 
EPI-AID funds will be used only for expenses incurred while 
conducting investigations approved by the Division of Training, 
EPO.
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VI. After the EPI-AID Investigation
Following completion of the investigation, several administrative procedures and reporting requirements must be completed.
At the conclusion of the EPI-AID investigation, the officer should 
contact the EPI-AID Coordinator immediately upon return. At this 
time, the officer will be scheduled to provide a two-minute oral 
update of the investigation at Epidemiology Grand Rounds. At a 
future date, the officer may be requested to present a more 
comprehensive report of the methods and results of the 
investigation as the main presentation at Epidemiology Grand 
Rounds.
Within five working days of return, the travel voucher should be 
prepared. The original and two copies of both the voucher and 
receipts should be forwarded to the EPI-AID Coordinator. After 
review, the EPI-AID Coordinator will forward the voucher to the 
Assistant Director for Operations, Division of Training, EPO, for 
approval. The Division of Training, EPO, will then be responsible 
for forwarding all approved vouchers to the Financial Management 
Office for payment. More detailed instructions are provided in 
Appendix 2.
It is important that the inviting local official receive a timely report 
of the field investigation and that the Division of Training, EPO, 
receive adequate documentation of EPI-AID field activities. 
Therefore, within 14 days of the officer’s return, the EPI-AID Trip 
Report should be completed and forwarded to the Division of 
Training, EPO. This report documents the early findings of the 
investigation and should describe (1) what was known about the 
problem at the beginning of the investigation; (2) what was done in 
the field, including recommendations; and (3) what is pending or 
planned for the future. It should emphasize the proceedings of the 
field investigation, should contain the results and recommendations 
presented in the exit briefing, and is not intended to be the final 
report of the study. A summary letter to the local health official 
may be substituted for the EPI-AID Trip Report if it contains the 
items required in the EPI-AID Trip Report. Examples are provided 
in Appendix 5 and Appendix 6.
While the EPI-AID Trip Report has no required format, a suggested 
outline is as follows:
■ Abstract or summary
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■ Results obtained in the field
■ Brief discussion of findings obtained in the field 
(interpretation of results obtained in the field within the 
context of information available at that time)
■ Recommendations made and actions taken in the field
■ Future plans (additional analyses, lab studies pending or 
planned, multivariable modeling, etc.)
Although the EPI-AID Trip Report is considered an internal 
document with limited distribution, it may be subject to disclosure 
under either the Freedom of Information Act (FOIA) or the Privacy 
Act. Therefore, it is important to keep the following considerations 
in mind when writing the EPI-AID Trip Report:
■ Use of Personal Identifiers — Based on advice from the CDC 
Office of General Counsel, personal identifiers of persons 
who are the subject of reports, such as an EPI-AID Trip 
Report, should not be brought back to Atlanta from the field 
unless this is necessary for public health purposes. Although 
data collected in the course of an EPI-AID are considered 
confidential and normally have limited distribution, they may 
not be exempt from disclosure under either the FOIA or the 
Privacy Act. Inadvertent releases of these reports are possible 
and could constitute an invasion of the subject’s privacy. In no 
case should a subject’s name (or means of identifying 
him /her) be included in a report of an EPI-AID investigation.
■ Preliminary Information — If a program wishes to emphasize 
the preliminary nature of the data and interpretations made, 
a paragraph may be placed on an EPI-AID Trip Report. An 
example of possible wording is as follows:
This Trip Report summarizes the field com ponent o f our 
EPI-AID investigation. Because o f the prelim inary nature of 
this investigation, it is possible that future correspondence,
M M W R  articles, o r o ther published reports may present results, 
in terpretations, and recom m endations that are somewhat 
different from  those contained in this docum ent.
The EPI-AID Trip Report does not need formal Division or Center 
clearance. Rather, it is a memo addressed to the Director, Division 
of Training, EPO. The trip report should be signed by the EIS 
officer and routed through the immediate supervisor on the 
EPI-AID investigation. The EIS officer’s primary supervisor (who 
may or may not be the immediate supervisor on the EPI-AID) 
should provide guidance in preparing the Trip Report. All CIO 
reviewing officials should give a high priority to timely review of 
these reports.
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When a summary letter to the local health official is substituted for 
the EPI-AID Trip Report, a cover memo should be addressed to the 
Director, Division of Training, EPO, noting that the attached letter 
is being submitted as the EPI-AID Trip Report (Appendix 6).
The EIS officer should make certain that the state epidemiologist 
and any other health official who issued the EPI-AID invitation 
receives a copy of the EPI-AID Trip Report (or summary letter). 
Distribution of other copies will be the responsibility of the 
individual program. We urge that the groups included on the EPI-1 
receive either this report or a subsequent report of your activities. 
However, EPO will not distribute any copies of the trip report.
As referenced in Section II, whenever data collection occurs in an 
EPI-AID (which is most o f the time), CDC is required to document 
the data collection activities for each EPI-AID. Therefore, 
investigators are required to: (1) complete the “Emergency 
Epidemic Investigations” form (Appendix 7); (2) attach a copy of 
the survey questionnaire used in the EPI-AID; and (3) submit these 
two documents to the Division of Training, EPO, as attachments to 
the EPI-AID Trip Report.
Frequently the results obtained from an EPI-AID investigation are 
later documented in a final report, an MMWR article, or journal 
article. The Division of Training is interested in the final disposition 
of all investigations related to EPI-AIDs. Therefore, the EIS officer 
or CDC program should send a copy of all publications related to 
the EPI-AID investigation to the Division of Training, EPO.
Trip Reports and other written reports on the EPI-AID 
investigation can be released to persons outside CDC when 
requested under the FOIA. A requestor must make the request in 
writing to the CDC FOIA Officer for processing. The program 
conducting the investigation, and not EPO, is responsible for 
responding to requests for EPI-AID reports. All requests for such 
documents made to EPO will be referred to the responsible 
program. This will permit the programs, in consultation with the 
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Appendix 1
Instructions for Preparing and Processing EPI-1 Reports
The preparation of an EPI-1 report begins immediately following approval of an EPI-AID and 
should be completed expeditiously, ideally within two days of when the EPI-AID number is 
issued. An example of a completed EPI-1 is presented on pages 24-25.
These instructions cover the entire process from preparation to distribution, as follows:
Preparing the Draft EPI-1 Report
Step-by-step instructions for preparing an EPI-1 are provided on pages 26-29. The format for an 
EPI-1 report is available in a WordPerfect merge document and may be obtained through E-mail 
from the EPI-AID Coordinator (404/639-3182).
Obtaining EPO Approval
Because of the need to convey the information quickly to public health officials, the draft EPI-1 
report must be completed and submitted to EPO for approval within 24 hours of when the 
EPI-AID number is assigned. The draft EPI-1 should be sent the the EPI-AID Coordinator via 
E-Mail or FAX (404/639-2222).
Preparing the Final EPI-1 Report
Following approval by Division of Training, EPO, the EPI-AID Coordinator will return the draft 
EPI-1 to the initiator (via E-Mail or FAX) for corrections, final formatting, and signatures from 
the appropriate division director(s). In the past, EIS insignia paper was used for the final 
camera-ready copy. Please note that EIS insignia paper is no longer required.
Preparing and Submitting the Print Request
The Management Analysis and Services Office (MASO) will print the required number of 
copies of the EPI-1 report. A Request for Printing Services (CDC Form 0.103A) form should be 
completed; detailed instructions for completing this form are provided on pages 30-31.
The camera-ready copy of the EPI-1 report should be attached to the Request for Printing 
Services (CDC 0.103A) and delivered to the Publications Management Section, Management 
Services Branch, MASO, Building 1, Room B122. Same-day processing is possible if your copy 
and requisition reach them by 3 p.m.
Distribution of the EPI-1 Report
MASO will distribute copies to all individuals included in the Mailing Keys. However, the 
initiating office is responsible for distributing copies of the EPI-1 report to any additional 




DEPARTMENT OF HEALTH & HUM AN SERVICES Public Health Service
EPI-AID: EPI-93-08-1
Centers for Disease Control 
and Prevention (CDC) 
Atlanta GA 30333
DATE: October 19, 1992
TO: Director, Centers for Disease Control and Prevention (CDC)
FROM: Director, Parasitic Diseases Division (DPD) 
National Center for Infectious Diseases (NCID)
SUBJECT: Pinworm Outbreak in Day-Care Center 
LOCATION: Georgia
Nature of Problem:
On October 15, CDC was notified that staff at a metropolitan day-care center had observed pinworms 
on nine infants and eleven toddlers in the previous 2 days.
Date Problem First Identified bv Requesting Agencv:
October 15, 1992
Date of Initial CDC Contact:
October 15, 1992
Initial CDC Contact:
Robert S. Pond, M.D., Epidemiology Activity (EA), DPD, NCID
Caller/Correspondent:
Director of a day-care center in Georgia
Source of Invitation:





EPO, DT, EISP 
EPO, DFE, SB
NCID, DPD 
NCID, DPD, PDB 
NCID, DPD, PDB, EA
Robert L. Kaiser, M .D., Director 
Victor C. W. Tsang, Ph.D., Acting Chief 
Dennis D. Juranek, D.V.M ., M.Sc., Chief 
Robert S. Pond, M .D., EIS Officer 
Willard Cates, Jr., M .D., M .P.H., Director 
Jean M. Heslin, Program Analyst 
John M. Horan, M .D., M .P.H., Chief
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Appendix 1 (cont’d.)
Example: EPI-1
Page 2 - Director, CDC
Other Persons Contacted
State/Local Health Officials:
J. David Smith, B.S., Assistant State Epidemiologist, DHR
James C. Crutcher, M.D., District Health Officer, District 3/Unit 4, DHR
Patti Lowe, R.N., M .P.H., District Chief of Nursing, District 3/Unit 4, DHR
Regional Office:
Max Pesses, Director, Division of Preventive Health Services, HHS Region IV, was notified on 
October 19, 1992.
Other (Non-CPC) Federal Officials:
Nature and Timing of Response:
Beginning on October 20, Dr. Pond will assist state and local health officials with an epidemiologic 
investigation of the outbreak.
Anticipated Duration of Field Investigation:
10 days




CDC Supervisor Responsible for Technical Supervision of Investigator and EPI-AID Trip 
Report:
Dennis D. Juranek, D.V.M ., M.Sc.
Objectives of the EPI-AID Mission:
To assist the state in investigating the outbreak and evaluating the effectiveness of control measures.
Distribution:
Mailing Keys WF-1, -2, -3; ZW
James C. Crutcher, M .D., District Health Director, District 3/Unit 4, and 
Patti Lowe, R.N., M .P.H., District Chief of Nursing, District 3/Unit 4,
Georgia Department of Human Resources, 101 South Perry Street, Lawrenceville, GA 30315 
J. David Smith, B.S., Assistant State Epidemiologist, Epidemiology Section, Department of Human 




Robert L. Kaiser, M.D. 
Director, DPD, NCID
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Preparing the EPI-1 Report
s.KWC,
/  ^
|  DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service





TO : (3) Director, Centers for Disease Control and Prevention
SUBJECT (4)
LOCATION : (5)
Nature o f  Problem: (6)
Date Problem  First Identified bv the Requesting Aeencv: (7)
Date o f  Initial CDC Contact: (8)
Caller/Correspondent: (9)
Source o f Invitation: (10)
CDC Staff Contacted (11)
CIO/Division/Branch/Section Nam e/Title
(12) (13)
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Appendix 1 (cont’d.)
1. Type the EPI-AID number provided by the EPI-AID Coordinator, Division of Training, EPO.
2. Type the date the EPI-AID number was issued.
3. Type “Director, Centers for Disease Control and Prevention.” Note: The EPI-1 report is al­
ways addressed to the Director, CDC.
4. The subject is a brief title of the health problem.
5. Type the state or city and state where the urgent health problem exists.
6. Provide a short statement of the problem (1-3 sentences). Both the seriousness and urgency 
of the problem should be evident from the language chosen. Mention of the history lead­
ing up to the request or of the request itself is discouraged.
7. Type the date the requesting agency first identified the problem.
8. Type the date the requesting agency contacted CDC.
9. Type the name of the person contacting CDC.
10. Type the name(s) and title(s) of the person(s) requesting epidemiologic assistance. This is 
usually a state health official. However, some EPI-AID requests may come from other 
sources (e.g., Indian Health Service, Federal penitentiary, hospital, cruise ship). In such 
situations, the CIO responding to the request is responsible for informing the state epidemi­
ologist and seeking concurrence. Regardless of the initial source of the request, in all cases 
the state epidemiologist must be one of the inviting officials.
11. This section documents all CDC staff contacted about the investigation. Occasionally, EPI- 
AID requests involve participation of more than one EIS officer (EISO) and more than one 
CIO. When preparing the EPI-1 report, include names, titles, and organizational affili­
ations of all participating EISOs.
12. Type in acronym form, e.g., NCID/DBMD/EDB/EDES.
13. Type full name, degrees, and title of all persons contacted.
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Appendix 1 (cont’d.)
Preparing the EPI-1 Report
Page 2 - Director, Centers for Disease Control and Prevention
Other Persons Contacted (14)
State/Local Health Officials: (15)
Other (Non-CPC) Federal Officials: (16)
Others: (17)
Regional Office: (18)
Nature and timing of Response: (19)
Anticipated Duration of Field Investigation: (20)
Branch/Division/CIO Providing Primary Oversight of the Investigation: (21)
CIO Sharing Oversight: (22)
CDC Supervisor Responsible for Technical Supervision of Investigator and EPI-AID Trip 
Report: (23)
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Appendix 1 (cont’d.)
14. This section documents all non-CDC persons contacted concerning the EPI-AID investiga­
tion.
15. Type names, titles, and locations of all individuals contacted in the state and local health de­
partments.
16. Type names, titles, and locations of all individuals contacted in the (non-CDC) Federal gov­
ernment. If none, type “none.”
17. Type names, titles, and locations of all individuals contacted. If none, type “none.”
18. Type the name, title, and location of the person contacted in the Division of Preventive 
Health Services in the appropriate regional office responsible for the area(s) of the country 
in which the outbreak occurs. In most cases, the Director, Division of Preventive Health 
Services (or designee) is listed.
19. Provide a brief statement including the name of the EISO assisting in the investigation and 
when the officer will depart. Remember: EISOs are “assisting” in, not “conducting, ” the investi­
gation.
20. Type in the length of time verbally agreed upon by EPO and the CDC program when the 
EPI-AID investigation is initiated (usually not to exceed three weeks).
21. Type in acronym form the Branch/Division/CIO accepting primary responsibility for assist­
ing in this investigation, e.g., EDB/DBMD/NCID.
22. Type the acronym of the CIO(s) sharing oversight. If none, type “none.”
23. Type the name, title, and location of the person who will supervise the EISO(s) involved in 
the EPI-AID and provide guidance for writing the EPI-AID Trip Report.
24. Provide a brief statement describing the objectives, e.g., “To identify the cause and risk fac­
tors . . .” or “To assess the extent of Disease X in the population . . .”.
25. The only signature required is that of the division director of the program responsible for 
the EPI-AID investigation. The signature block should be typed as it appears in official cor­
respondence. If more than one division is involved, all other division directors’ signatures 
should be included.
26. Type the following mailing keys: WF-1,-2,-3, ZW. These mailing keys include all first- and 
second-year EIS officers, EPO and CDC professional staff, and all state epidemiologists. Be­
low the mailing keys, list the names, titles, and complete mailing addresses of all other per­
sons who are to receive copies of the EPI-AID documents (i.e., those with whom the 
investigation has been discussed who are not included in the mailing keys).
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Preparing the Print Request
S u bm it to : Management Analysis and Services O ffice  (M ASO)
P ublications Management Section. Bldg. 1, Rm. B122, [mail stop A 18)
This fo rm  is to  be used fo r:
Publications and Forms Printing, Graphics, Mailing and Distribution.
REQUEST FOR PRINTING SERVICES
(  SEE IN S T R U C T IO N S  O N  BACK O F CO PY 9  )
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2215
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Ann H. Wiman, Director, Administrative Svcs.
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Appendix 1 (cont’d.)
1. This date is the same as that o f the EPI-1 report.
2. This is the same date as 1. above. Type “MUST” behind the date in the space provided.
3. Type the name of the responsible branch/section and CIO division, including a mailstop 
code.
4. Type the name and telephone extension of the person to call if MASO has questions about 
the information on the request.
5. Type the name and title of the CIO administrative officer.
6. Type the EPI-1 report number and subject.
7. In this space, type “Information for professional personnel.”
8. Check two boxes: New and Camera Ready Copy.
9- No information required.
12.
13. Check two boxes—Both Sides and Head-to-Foot.
14. Check one box—Single Sheets.
15. Type in the word “keys” and the number of extra copies needed to distribute to individuals 
listed in the EPI-1 report who are not on the Mailing Keys.
16. Type “2” or “3”. The EPI-1 should be no more than two to three pages in length.
17. Type “8-1/2” x “11”.
18. No information required.
19. Type “offset” for Text-Grade or No.
Type “white” for Text-Paper Color.
Type “black” for Text-Ink Color.
20. No information required.
21. No information required.
22. No information required.
23. No information required.
24. No information required.
25. On Line 1, under Effective Date, type in the same date as in Item 1.
On Line 1, under CAN, type the CAN number for the responsible CIO.
26. Type “WF-1,-2,-3; ZW.”
27. Type “Distribution, MASO, Mailstop A23” and the number of extra copies requested in 
Item 15. above, to the person designated to mail copies to those individuals listed in the Dis­




Instructions for Preparing and Processing EPI-AID Travel
These instructions are provided to assist CDC staff in preparing EPI-AID travel documents when 
EPO funds are being used. The travel order, including all travel arrangements (airline tickets, 
hotel accommodations, etc.) and the travel voucher are prepared by the traveler’s CIO. Unlike 
other travel prepared by CIOs, however, supporting documents for EPI-AID travel must be 
prepared manually using a Travel Order HHS-1 (Rev. 7/89) form and a Travel Voucher 
Standard Form 1012 (Rev. 10-77).
NOTE: Modifications to the CDC computerized travel system are now being pilot-tested so 
that travel performed by one CIO can be authorized and paid by another CIO. Therefore, in 
the very near future, CIOs will be able to complete EPI-AID travel on-line.
Preparing the Travel Order
Instructions for preparing an EPI-AID travel order are provided on pages 34-35. These 
instructions highlight the requirements specific to an EPI-AID; guidance on completing other 
sections of the travel order can be obtained from the administrative office in the traveler’s CIO.
Preparing a Confirmation Travel Order
A confirmation travel order must be prepared when the traveler is required to travel before a 
regular travel order can be prepared (after normal business hours or on weekends). The 
instructions for completing a confirmation travel order are the same as that for a regular travel 
order with the following exceptions:
■ Type “CONFIRMATION” in the upper left corner preceding “TRAVEL ORDER.”
■ In item 10, complete the statement “Traveler was directed by (name) on (date) to perform 
official travel from (originating city and state) to (destination city and state) and return.” 
Complete the remainder of item 10 as required (purpose of travel, authorization for taxis, 
etc.).
Processing the Travel Order
■ After the travel order is typed (and before it has been approved), FAX a copy of the un­
signed travel order to the EPI-AID Coordinator (FAX Number 404/639-2222) for purposes 
of tracking and accountability.
■ Prior to obtaining the signature of the authorizing official in the CIO, the travel order 
should be reviewed through usual administrative channels of the CIO.
■ After signatures are obtained, two copies of the travel order should be sent through interof­
fice mail to the EPI-AID Coordinator (Mailstop C08).
■ Distribute copies of the signed travel order as follows:
• Original to traveler.
• Blue and white tissue copy to Financial Management Office, Mailstop E12.
• Yellow tissue copy for advance of funds, if applicable.
• Green tissue copy to be retained by the office preparing travel for submission with the 
travel voucher.
• Pink, salmon, and gold tissue copies are for CIO use.
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Preparing the Travel Amendment
An amendment to the original travel order must be prepared when the points of travel change 
or an extension of more than two days is approved. [When a travel extension of one to two days 
is approved, the statement in item 10 “Traveler is authorized variation of itinerary of not more 
than 2 days at temporary duty in order to perform official business (REF JFTR U2135A)” waives 
the requirement for a travel amendment]. Complete only those items which reflect a change, as 
follows:
■ In the upper left corner, check [ ] Amendment, and type “1,2, 3” etc. in N o .___to indi­
cate whether this is the 1st, 2nd, 3rd amendment, etc.
■ Item 3. Type the amount increased or decreased, if applicable (i.e., when the change in 
points of travel or duration of travel affect the estimated cost).
■ Item 8 and Item 9. Type the revised dates of travel, if applicable.
■ Item 10. List each change separately; for example, type
“Amend item 3 as shown.”
“Amend item 8 as shown.”
“Amend item 9 as shown.”
“Increase/decrease funds in item 14 as shown.”
Item 14, Column 52-63. Type the amount increased or decreased, if applicable.
Item 14. Column 65-79. Type “INCREASE” or “DECREASE” corresponding to the amount 
in Column 52-63.
Preparing and Processing the Travel Voucher
■ When the traveler returns, a Travel Voucher (Standard Form 1012) should be completed. 
Guidance for completing the voucher can be obtained from the administrative office in the 
traveler’s CIO.
■ The traveler should sign the voucher and forward to the EPI-AID Coordinator within
5 working days of return the following: the original voucher and two copies, the original re­
ceipts and one copy, and the green tissue copy of the travel order.
■ After review, the EPI-AID Coordinator will forward the voucher to the Assistant Director 
for Operations, Division of Training, EPO, for approval.
■ The Division of Training, EPO, will then be responsible for forwarding the approved 
voucher to the Financial Management Office for payment.
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Preparing the EPI-AID Travel Order
DEPARTMENT OF HEALTH ANO HUMAN SERVICES
TRAVEL ORDER
H  Original □  Amendment No. . □  C a nce lla tio n
(See HHS Travel Manual. Part 3. for Detailed Instructions)
4  NAME ANO POSITION OR RANK
Name of Traveler
EIS Officer or Medical Elective Student
1 TRAVEL OROER NO
E_____







I APPROX DATE OF DEPARTURE
f  PRESENT OFFICIAL STATION )  APPROX DATE OF RETURN
y Q ITINERARY AND PURPOSE OF TRAVEL (Show city, atata or country, d a f*  and raaaona—uaa continuation » h a t 0 nacaaaary)
FROM: City, State to City, State, and return.
PURPOSE: EPI-— -— . To assist State and local health department officials investigate an 
outbreak of . . .  .
Use of local transportation facilities, including taxis, is authorized when advantageous 
to the Government and justified on the voucher. Traveler is authorized variation of 
itinerary of not more than 2 days at temporary duty in order to perform official business 
(REF JFTR U2135A).
NOTICE: TRAVELERS ARE RESPONSIBLE AND LIABLE FOR UNUSED QTR'S — TICKETS RECEIVED UNTIL THEY HAVE 
BEEN PROPERLY ACCOUNTED FOR ON A TRAVEL VOUCHER OR RETURNED TO THE AGENCY.
TRAVEL BY PRIVATELY OWNED AUTO IS AUTHORIZED ON MILEAGE 
BASIS RATE SPECIFIED BELOW FOR:
□  EMPLOYEE AND/OR
_« PER MILE AS MORE 
ADVANTAGEOUS TO 
GOVT




_C PER MILE NOT TO 
EXCEED COSTS BY 
GOVT-OWNEO AUTO
□  GSA AUTO □  AUTO RENTAL UNDER GSA CONTR
□  EXCESS BAGGAGE □  REGISTRATION FEE









TRANSPORTATION OF □  DEPENDENTS
□  H/H GOODS & PERS EFFECTS
□  TEMPORARY 
STORAGE
□  RESIDENCE 
TRANSACTIONS
□  MISC EXP 
ALLOWANCE □  OTHER 
(S p to ly i
□  NOT REQUIRED
| 2  TRAVEL t PER OtEM IS AUTHORISED IN ACCORDANCE WITH DHHS POLICY ANO 
□  FTR* □  JTR’S □  OTHER (Sp9Cityl
TO BE PERFORMED FOR IOHHS. UN. #fc I
CDC
PER DIEM □  NONE 
R A T E *________________
□  IN U S. □  OUTSIDE U S  □  VARYING RATES
PER ABOVE REGS
□  LOGGINGS PLUS □  ACTUAL EXPENSE □  FIXED
EXPENSES 10 BE PAID BY
CDC
J 4  ACCOUNTING DATA /Saa HHS A cctg  Manual A A cctg  Coda Book)
SECURITY APPROVAL GRANTED FOR TRAVEL OF 
□  90 OAYS OR LESS □  OVER 90 DAYS DATE .
RESPONSIBLE FOR SECURITY CLEARANCE 















I ü  
1 q
S
O R IG IN A L
OBLIG ATIO N
O THER





































































ISNAME ANO TITLE OF OFFICER RECOMMENOING ABOVE TRAVEL
AUTHORITY IS HEREBY GRANTED TO PERFORM TRAVEL AND TO INCUR SUCH EXPENSES AS MAY BE NECESSARY UNOER THE CONDITIONS SET FORTH ABOVE
TITLE ------------------------------------------------------------------------------------------- ------ -
AUTHORIZED BY_____________________________________________________________________ OATE ____________________________________________ — ------------------
* To ba cow p W x l by Offtca Initialing Travel Or&n. Olha» Accounting Data to ba Complatad by Fiscal/Accounting Off*c«
HHS-1 (REV. 7199) TRAVELER
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1. A travel order number can be obtained by contacting the EPI-AID Coordinator at 
404/639-3182. The travel order number consists of seven characters. The first character,
E, identifies the travel order as being associated with an EPI-AID investigation, the next two 
characters identify the current fiscal year, and the last four characters are assigned by the 
EPI-AID Coordinator.
2. The appropriation number is a seven-digit number that remains the same each year with 
the exception of the third digit that changes each fiscal year. In FY 1993, the appropriation 
number is “7530943; in FY 1994, type ”7540943, etc."
3-9. Self-explanatory; see CIO administrative office if assistance is needed.
10. For itinerary, complete the following statement “FROM (originating city and state) TO 
(destination city and state), and RETURN” and type in the space provided.
For Purpose, type the EPI-AID number assigned by the EPI-AID Coordinator. This number 
identifies the specific EPI-AID investigation and is used for programmatic tracking purposes. 
This number is not the same as the EPI-AID Travel Order No. listed in item 1. After typing 
the EPI-AID number, continue with a brief statement describing the purpose of the travel.
After Purpose, type “Use of local transportation facilities, including taxis, is authorized 
when advantageous to the Government and justified on the voucher. Traveler is authorized 
variation of itinerary of not more than 2 days at temporary duty in order to perform offi­
cial business (REFJFTR U2135A).”
11 - Self-explanatory; see CIO administrative office if assistance is needed.
13.
14. Complete only the columns listed below:
Column 2-7, Eff. Date: type the date the travel order is prepared.
Column 16-25, Document No.: type the same entry as in item 1. Travel Order No.
Column 40, Fiscal Year: type the last digit of the fiscal year, e.g., type “3" for FY 1993.











C o lu m n  48-51, 
in te rn a tio n a l.
O bj. C lass
Column 52-63, Amount Dollars & Cents: type the total amount that needs to be obligated 
for this travel. This amount is usually the sum of estimated Per Diem and O ther expenses 
listed in item 3, since the cost for airfare, when arranged through SATO, is obligated sepa­
rately. However, this amount is the cost of transportation added to Per Diem and Other 
listed in item 3, when transportation is not arranged by SATO, such as when the traveler 
uses a privately-owned vehicle (POV) OR Government Transportation Request (GTR), 
Diners Club card, or cash during nonbusiness hours or weekends.
15. Self-explanatory; see CIO administrative office if assistance is needed.
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CREW SURVEY QUESTIONNAIRE in CDC USE ONLY 
CODE = 2(1)
ID = ---------------- (2-6)
Dear Crew Member:
The U.S. Public Health Service is conducting a survey of the health status of passengers on this vessel. 
To assist us, please answer the following questions:*




4. Nationality (28-47) 5. State (48-50)
6. Cabin Number (85-90) 7. Number of persons in your cabin (91-92) 8. What is your rating or occupation? (104-123)
9. Were you III with vomiting or diarrhea (3 or more loose or watery bowel movements In a 24-hour period) during this cruise? (124) 
Circle One: 1 Yes 2 No 3 Not Sure 
If yes, please answer (a) through (e).
(a) Which of these symptoms did you experience? (Circle "Yes", "No", or "Not Sure" for each symptom):
1 2 3 1 2 3
Diarrhea Yes No Not sure (125) Headache Yes No Not sure (129)
Vomiting Yes No Not sure (126) Fever Yes No Not sure (130)
Abdominal Cramps Yes No Not sure (127) Blood in Stools Yes No Not sure (131)
Nausea Yes No Not sure (128) Sore Throat Yes No Not sure (132)
Muscle Aches Yes No Not sure (133)
(b) When did your symptoms begin? (Give date and time and circle a.m. or p.m.)
Oate /
MO DA YR
.(134-139) Time _ .(140-143) a.m. p.m.
(c) Were you seen by the ship's medical staff during the cruise? (144) 
Circle One: 1 Yes 2 No 3 Not sure
(d) Are you still III? (145) 
Circle One: 1 Yes 2 No 3 Not sure
(e) If your illness is over, how many days were you ill?
__________ Number of days ill (146-147)
10. Did you miss work because of your illness?
O.irrlft Onp- 1 Y r s  ? Nn (i45i) If yes. how many days did you m iss? (150-151)
11. What is  the source of the water you drink? (152) 
Circle One: 1 Tap only 2 Bottled only 3 Both 4 Never drink water
12. If you were ill, what do you think caused it?
•PROTECTION OF PRIVACY INFORMATION
Public Law 93-579 entitled the Privacy Act of 1974 requires that Individuals asked to furnish Information such as that 
requested in this form be Informed of the purpose for collecting such lnformaUon and what the Information will generally be 
used for.
The following Information is accordingly provided:
Authority: The Centers for Disease Control, an  agency of the Department of Health and Human Services. Is authorized to 
solicit the information requested in this form under the authority of the Public Health Service Act, Section 301. 361 
(42 U.S.C. 241,264).
Purpose and Uses: The lnformaUon requested will be used to implement appropriate control m easures If any health 
problems are ldenufied, and may be shared with federal, sta te and local health authorities. An accounting of such 
disclosures will be made available to you upon request.
Effects of Non-Disclosures: Your disclosure of the requested Information Is voluntary, and no penalty will be imposed If 
you choose not to respond. However, if you do not fill out the quesUonnalre. It wll be more difficult for u s  to determine 
the health sta tu s of the persons on th is cruise.
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
PUBLIC HEALTH SERVICE  
CENTERS FOR DISEASE CONTROL 
ATLANTA. GEORGIA 30333
Pubic reporting burdan of thia colacbon of Information ia aatimatad to avarag« 3 minutaa par raaponaa, indudng tha tima for raviawing Inatructona. aaarching awsting data 
aourcaa, gathahng and maintaining tha data naadad. and conpM ng and raviawing tha coOaction oI Information. Sand commanta ragarding thia burdan aatimata or any othar 
aapact of thia colacbon of Information, induding suggaationa for radudng thia burdan, to PHS Raports Claaranca Officar. ATTN: PRA; Hubart H. Humphray Bldg., Rm. 721-B; 
200 Indapandanca Ava.. SW; Waahington, PC 20201, and to Iha Offica of Managamant and Budgat: Papanwork Raduction Projact (0020-0006); Waahington. PC 20503.
C D C  7 5 .1 2 A  ( f .  4 .4 1 0 B )  FORM APPROVED
REV. 9-91 °MB NO. 0020^006
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PASSENGER SURVEY QUESTIONNAIRE in CDC USE ONLY 
CODE = 1 (1)
ID e ____________ (2-6 )
Dear Passenger:
The U.S. Public Health Service is conducting a survey of the health status of passengers on this vessel. 
To assist us, please answer the following questions:*
1. Name Last (7-16) First (»7-24) 2. Age (25-26) 3. Sex (27)
Circle One: 1 Male 2 Female
4. Address






.Telephone Number: (area code).
5. At which port did you board the ship? (80-84) 10. Circle the average number of g lasses of ship’s water you drank per day (100-101) 
(If you were ill, circle the average per day before you became ill)
0 1 2 3 4  5 6 or more6. Cabin Number (85-90) 7. Number of persons In your 
cabin (91-92)
11. Circle the average number of beverages containing ice you drank per day (102-103)
(If you were ill, circle the average per day before you became ill)
0 1 2 3 4 5 6 or more
8. Dining Table Number
(93-98)
9. Sitting (99)
Circle One: 1st 2nd 3rd
12. Were you III with vomiting or diarrhea (3 or more loose or watery bowel movements in a 24-hour period) during this cru ise? (124) 
Circle One: 1 Yes 2 No 3 Not Sure 
If yes, please answer (a) through (f).
(a) Which of these symptoms did you experience? (Circle 'Y es ', "No", or "Not Sure" for each symptom):
1 2 3 1 2 3
Diarrhea Yes No Not sure (125) Headache Yes No Not sure (129)
Vomiting Yes No Not sure (126) Fever Yes No Not sure (130)
Abdominal Cramps Yes No Not sure (127) Blood in Stools Yes No Not sure (131)
Nausea Yes No Not sure (128) Sore Throat Yes No Not sure (132)
Muscle Aches Yes No Not sure (133)
(b) When did your symptoms begin? (Give date and time and circle a.m. or p.m.)
Date . J.___ L. .(134-139) T im e . .(140-143) a.m. p.m.
(c) Were you seen by the ship's medical staff during the cru ise? (144) 
Circle One: 1 Yes 2 No 3 Not sure
(d) Are you still III? (145) 
Circle One: 1 Yes 2 No 3 Not sure
(e) If your illness is  over, how many days were you ill?
__________ Number of days ill (146-147)
(f) Were you confined to your cabin by your illness? (148) 
Circle One: 1 Yes 2 No 3 Not sure
13. If you were III, what do you think caused It?
•PROTECTION OF PRIVACY INFORMATION
Public Law 93-579 entitled the Privacy Act of 1974 requires th a t Individuals asked to furnish Information such  as  tha t requested In th is form 
be Informed of the purpose for collecting such  inform ation and  w hat the Information will generally be used for.
The following Information is accordingly provided:
Authority: The Centers for D isease Control, an  agency of the D epartm ent of Health and  H um an Services. Is authorized to solicit the 
Information requested In th is form under the  authority  of the Public Health Service Act. Section 301. 361 
(42 U.S.C. 241.264).
Purpose and Uses: The Information requested will be used  to Implement appropriate control m easures If any health  problem s are Identified, 
and  may be shared  with federal, s ta te  and local health  authorities. An accounting of such  disclosures will be m ade available to you upon 
request.
Effects of Non-Dlaclosuras: Your disclosure of the requested Information Is voluntary, and  no penalty will be Imposed If you choose not to 
respond. However. If you do not Dll o u t the  questionnaire. It wll be more difficult for u s  to  determ ine the health  s ta tu s  of the persons on 
th is cruise.
DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE 
CENTERS FOR DISEASE CONTROL 
ATLANTA. GEORGIA 30333
Pubic raportng bunten of thia colacMon el ititormafon i t  MtmtMd to avaraga 3 trinutaa par raaponaa. indudng tha lim« tar m iM ing inatiueaona. aaaiddng axia«ng data 
■ouroaa. gathanng and matfnuinng tha data naadid. and conpM ng and rawawng tha colac ton 04 intonnalion. Sand conwnanla raganftng H a  burdan aabmata or any othar 
a ^ a c to ftN a oc l l tHnnolM oniH on, Indudino auggaatlona lor radudng IM  burdan, to PHS Rapom Claaranoa Officar ATTN: PRA:HubartH. Humphray Bldg.. Rm. 721-B; 
300 Indapandanca Aaa.. SW: WaaWngton. DC 2Qaoi. and to »ta Offica d  Managatnant and Budgal: P^anaorh Raductton Piojacl f0«20-000a). Waatanglon. DC 20903.
CDC 75.12B ((. 4.410C) FORM APPROVEDqcv 9-Q1 OMB NO 00200006
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Example: EPI-AID Trip Report
DEPARTM ENT OF H EA LTH  & HUM AN SERVICES Public Health Service
MEMORANDUM Centers for Disease Control
Atlanta GA 30333
Date: April 28, 1992
From: EIS Officer
Meningitis and Special Pathogens Branch, DBMD, NCID (C09)
Subject: EPI-AID Trip Report: Gastroenteritis on the Cruise Ship Regent Sun (Epi 92-42)
To: Willard Cates, Jr., M .D., M.P.H.
Director, Division of Training, EPO (C08) (~x//
Through: Assistant Director for Science, NCEHIC
Director, Division of Bacterial and Mycotic Diseases, NCID 
Chief, Enteric Diseases Branch, DBMD, NCID *7*
Chief, Epidemiology Section, EDB, DBMD, NCID J ^ T ... /
Chief, Meningitis and Special Pathogens Branch, DBMD, NCID
BACKGROUND
On March 13, 1992, Michael Trubenbacher, Operations Manager, Regency Cruises, 
contacted Donald W. Turner, Staff Sanitarian, Vessel Sanitation Program, Special 
Programs Groups, NCEHIC, to report diarrheal illness on the cruise ship Regent Sun. 
Eighteen (3.7%) of 482 passengers and one (0.2%) of 418 crew members were 
reported to have visited the ship’s infirmary because of gastroenteritis.
The ship was on a 7-day voyage in the Caribbean from March 8 to March 15, 1992, 
beginning and ending in San Juan, Puerto Rico. Ports of call included St. Lucia, 
Martinique, Dominica, St. Kitts, and St. Thomas. It was scheduled to arrive in 
San Juan on March 15 for passenger disembarkation. On March 14, Kenneth M. 
Zangwill, M.D., EIS Officer, Meningitis and Special Pathogens Branch, Division 
of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, and 
William A. Bower, epidemiology elective student, traveled to St. Thomas, U.S. Virgin 




On March 14, the ship’s infirmary logs were reviewed for visits for gastrointestinal 
illness during the cruise. The peak onset of illness was March 12. Standard CDC 
passenger and crew questionnaires were distributed, and a supplementary questionnaire 
requesting information regarding food eaten on board ship March 9-11 and during an 
offshore excursion to St. Lucia on March 10 was included with all passenger 
questionnaires. A case was defined as vomiting or diarrhea (three or more loose or 
watery stools in a 24-hour period) in a passenger or crew member with onset any time 
during the cruise. Controls included passengers who reported no such illness during 
this cruise.
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A follow-up telephone survey of persons who took the offshore excursion to St. Lucia 
(including guides and food handlers from the local excursion company) was conducted 
on March 21-22, 1992. Information regarding foods eaten, other activities, and clinical 
severity of illness was obtained. Other information regarding the preparation and 
handling of food served on this excursion was sought.
Descriptive analysis was based on the entire passenger data set. Analytic studies were 
performed in a case-control fashion with three randomly chosen controls per case.
Vessel Sanitation Inspection
A vessel sanitation inspection was conducted and included evaluation of the water 
supply, refrigeration, food storage and handling, general sanitation, and structural and 
equipment maintenance. Water purification equipment and records were reviewed and 
water samples collected.
Laboratory Investigation
Rectal swabs, whole stools, and blood samples were collected from ill and well 
passengers and crew members 24-72 hours after onset of symptoms. Rectal swabs 




Three hundred eight (64%) of 482 passengers and 400 (96%) of 418 crew members 
returned the questionnaire. Fifty-six passengers (18% of returned questionnaires) and
12 crew members (3% of returned questionnaires) reported illness meeting the case 
definition. Symptoms reported by more than 50% of ill passengers included diarrhea, 
abdominal cramping, nausea, headache, fever, and myalgia (Table 1). Twenty-four 
(43%%) ill passengers visited the ship’s infirmary, and 26 (53%) were confined to 
their cabin because of illness. The mean duration of illness was 6.2 days. Two 
passengers were hospitalized after disembarkation.
The mean age of ill passengers was 44 years (range 16-74). Attack rates did not differ 
by sex. Twenty-nine (52%) ill passengers and 10 (83%) ill crew members were 
female. No apparent association with cabin location was noted. The reported onset of 
illness peaked on March 11 and 12 with rapid decline thereafter (Figure 1). Of 56 
passengers who became ill, 44 (79%) took an excursion to St. Lucia on March 12.
In addition, three of six guides on this excursion became ill.
Analytic Epidemiologic Investigation
A case-control analysis of passengers revealed that participation in an excursion to 
St. Lucia on March 10 was associated with illness (odds ratio [OR] = 33.8, 95% 
confidence interval [Cl] =  13.5, 86.9, p = 10-7). This excursion is a regular weekly 
offering to Regent Sun Caribbean cruise patrons. It includes a land tour of various 
sites in the island and snorkeling in a cove that communicates with the Atlantic Ocean.
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A lunch buffet, catered by a private St. Lucia restaurant, was served on a catamaran 
during the excursion. Cohort analysis of passengers who took this trip revealed that 
consumption of the potato salad was associated with the development of illness (relative 
risk [RR] = 2.0, p = 0.01). The median time from this meal to onset of symptoms 
was 34-36 hours. Snorkeling and swallowing at least one mouthful of water while 
snorkeling during this excursion were not associated with illness. Eating lunch on 
board ship on March 10 was highly protective (OR = 0.06, Cl =  0.0, 0.1, p =  107). 
Having breakfast on the ship on March 9, 10, and 11, as well as lunch on March 11, 
was also protective for development of illness. No other meals served on the ship from 
March 9 to 11 or other foods served at the St. Lucia excursion meal were significantly 
associated with illness (Tables 2, 3).
No significant difference was found in the mean number of glasses of the ship’s water 
or iced beverages consumed by ill and well passengers.
The illness that afflicted passengers and crew who did not take the St. Lucia excursion 
was different from that which affected excursion participants. Ill passengers who took 
the St. Lucia excursion had a longer duration of illness (mean 7.8 vs. 2.6 days, 
p < 10'5) and significantly different symptom complex than ill passengers who did not 
take the St. Lucia excursion (Figure 1). No significant secondary spread was evident 
between ill excursion participants and other ill persons.
Comparison of ill passengers who did not take the St. Lucia excursion and healthy 
passengers did not reveal an association with a specific meal served on the ship nor 
with the mean number of glasses of ship’s water or iced beverages consumed.
Vessel Sanitation Inspection
The operation of the food and water systems on the Regent Sun was found to be in 
compliance. Some deficiencies in the structure and equipment of this ship were noted, 
but general operations of this ship were also found to be in compliance.
Laboratory Investigation
Nine of 13 rectal swab samples from ill passengers grew Shigella sonnei. This isolate 
was sensitive to standard antibiotics. All of these isolates were from persons who took 
the St. Lucia excursion. Swabs from 10 control persons did not yield Shigella, 
Salmonella, Campylobacter, Vibrio, or Bacillus cereus. No samples of any food served 
on the excursion were available for culture. No coliform bacteria were detected in the 
ship’s water.
DISCUSSION
The etiologic agent responsible for the outbreak of diarrheal illness on the Regent Sun 
was Shigella sonnei. It was transmitted via a meal served on an offshore excursion to 
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The breakfast meals noted to be protective for illness likely represent the active 
schedule of the generally younger ill passengers who took the St. Lucia excursion and 
who would, therefore, be more likely to miss breakfasts.
This meal served on the catamaran was provided by a privately owned restaurant on the 
island of St. Lucia. All food reportedly was prepared the day of the excursion, stored 
in coolers on the catamaran, and eaten approximately 4-5 hours later, buffet style. The 
potato salad was served from a large, shallow tray, and the majority of persons who 
are reported that it was of ambient temperature.
Shigella species are infrequently reported as the etiologic agent in cruise ship 
outbreaks (1), and S. sonnei, specifically, has not been previously reported in this 
setting. Although the implicated organism is not commonly found, the vehicle, potato 
salad, was implicated in 20% of all foodborne outbreaks of shigellosis reported to CDC 
form 1983 to 1987 (2).
Preparation of potato salad requires extensive handling of ingredients. Separation of 
the dry ingredients from the mayonnaise combined with inadequate refrigeration and a 
low inoculum of Shigella necessary for transmission (3), may have allowed for 
transmission of the organism through consumption of the potato salad.
No food handler who may have been ill before the St. Lucia trip was reported among 
the catamaran crew or from the food handling staff of the catering restaurant.
The Caribbean Epidemiology Center epidemiologist in Trinidad was informed of the 
outbreak. He will inquire further about ongoing shigellosis on St. Lucia.
RECOMMENDATIONS
1. Private caterers used by cruise ship companies should be held to the same food 
handling and preparation standards as the cruise ship, and if that is not possible, 
consideration should be given to avoiding the use of private caterers.
2. All passengers of the cruise ship should be notified of the cause of this outbreak 
and informed of appropriate therapeutic and preventive measures.
3. Any food handler with a gastrointestinal illness should be excused from duty until 
the illness has resolved.
4. The importance of handwashing for prevention of gastrointestinal illness should 
be reinforced, particularly among food handlers.
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5. Surveillance for gastrointestinal illness should continue with daily reports 
(including zero cases) to the Sanitation and Vector Control Activity in Miami for
the voyage beginning March 15, 1992.
6. The recommendations outlined in the vessel sanitarian’s report should be 
implemented.
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FIGURE 1. Outbreak of gastroenteritis among crew and passengers aboard a cruise 
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Table 2
Selected meal exposures 
among 56 ill passengers and 169 well passengers, 
Regent Sun, March 9-11, 1992
Exposure 
and date CasesN (%)
Controls 
N <%)
oddsratio 95% Cl P
Breakfast
3/9
40 (73) 157 (94) 0.17 0.1,0.4 10'7
Lunch
3/9
53 (96) 158 (94) 1.7 0.3,16.2 0.73
Midnight buffet 
3/9
18 (34) 35 (21) 1.8 0.9,3.7 0.13
Breakfast
3/10
41 (76) 154 (95) 0.30 0.1,0.8 0. 01
Lunch
3/10




42 (78) 14 (9) 33.8 13.5,86.9 10'7
Dinner
3/10
52 (96) 165 (99) 1.6 0.02,4.6 0.26
Midnight buffet 
3/10
20 (37) 41 (25) 1.6 0.81,3.3 0.19
Breakfast
3/11
41 (77) 150 (90) 0.41 0.17,1.0 0.05
Lunch
3/11
32 (62) 133 (81) 0.40 0.2,0.8 0.01
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Table 3
Food exposures among passengers on St. Lucia Excursion,
March 10, 1992
St. Lucia lunch 111 Well Relative 95% Cl P
N=44 N=15 Risk
N (%) N (%)
Baked Chicken 39 (89) 13 (87) 1.1 0.64,1.7 1.0
Potato salad 40 (91) 9 (60) 2.0 0.94,4.4 0.01
Rice dish 38 (88) 10 (67) 1.5 0.83,2.5 0.12
Cole slaw 32 (82) 8 (53) 1.3 0.87,1.9 0.21
Cake 21 (49) 7 (47) 1.0 0.75,1.4 0.82
Fruit juice 17 (44) 4 (27) 1.1 0.85,1.5 0.60
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Example: Summary Letter as EPI-AID Trip Report
Appendix 6
¿È MEMORANDUM
DEPARTMENT OF HEA LTH & HUM AN SERVICES Public Health Service
Centers for Disease Control 
Atlanta GA 30333
Date: September 25, 1992
From: EIS Officer
Epidemiology Section, Viral and Rickettsial Zoonoses Branch, Division of Viral 
and Rickettsial Diseases, NCID (G13)
Subject: EPI-AID 92-87 Trip Report
Director, Division of Training, EPO (C08) ^  
Through: Chief, Epidemiology Section, VRZB, DVRD, NCID jf___
The attached memo was submitted to local officials before leaving Siler City, 
North Carolina, on EPI-AID 92-87. I am submitting it as my EPI-AID Trip 
Report.
To: Willard Cates, Jr., M.D., M.P.H.
Mary Jane Schmidt, M.D.
Attachment
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To: John Shaw, Health Director, Chatham County
From: Mary Jane Schmidt, M.D., Centers for Disease Control
CC: R.A. Meriwether, M.D., North Carolina State Health Dept. Steve Pickard, M.D., North Carolina State Health Dept. Sue Fields, R.N., Chatham County Health Dept.
Preliminary Report to Chatham Co. Health DeptRocky Mountain Spotted Fever Outbreak, Bear Creek, North Carolina Investigation Dates: 9/1 - 9/12/92 Report Date: 9/12/92
BACKGROUND: In mid-August 1992 a sibling pair in Bear Creek. North Carolina became ill with Rocky Mountain Spotted Fever (RMSF). One child died and the other required ICU hospitalization. Four other persons in the community, including two children in day care with the index cases, were said to have symptoms consistent with RMSF. Because clustering of tick-borne disease is unusual, especially in 
a day care setting, the Chatham County Health Department in cooperation with the North Carolina State Health Department and the 
Centers for Disease Control (CDC) decided to investigate.
INDEX CASES: First the diagnoses of the index cases were confirmed. Hospital records at UNC Chapel Hill Memorial Hospital were reviewed. Both children had skin biopsy specimens which were
Positive for RMSF by direct immunofluorescence, a highly specific est. In addition, specimens will be taken to CDC in Atlanta for 
PCR (polymerase chain reaction) analysis.
REPORTED RELATED CASES: Family and day care contacts were interviewed and those who had been ill were tested for RMSF IgG antibody by the state lab. One of the two ill children in the day care had a positive titer of 1:64. Three probable cases in the same limited area at the same time are unusual. However, of the 
original sibling pair, only one child attended the day care; so no single area of outdoor exposure could be established for the three cases, and the report of a day care cluster was not substantiated.
SEARCH FOR ADDITIONAL CASES: To determine whether the area was 
experiencing a more widespread increase in incidence, additional 
cases in the community were sought in several ways.
1. Word of mouth: Because of community concern many cases were brought to the attention of the health department by simple word of mouth. Fourteen people who had been ill were interviewed and questionnaires regarding symptoms, tick exposure, and outdoor activity were completed. Serum specimens were obtained on 12 of14. One child, who was unrelated to the index cases, had been diagnosed with RMSF by his local physician (acute titer 1:64 on 8/27). A convalescent titer was drawn on this child.
2. Physician survey: All primary care physicians in Chatham County 
were contacted and asked if they had diagnosed any cases of RMSF since July 1. No additional serologically confirmed cases were identified. Most physicians treated empirically with tetracycline if fever or headache and history of tick bite were present. None felt that they had seen more possible RMSF cases this summer than 
in previous summers, although several reported they were seeing
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more patients for tick removal than in the past.Three possible cases were identified. One had a negative antibody titer, one had equivocal titers, and one has titers pending.
3. Emergency room record review: The Chatham Hospital ER log was 
reviewed for the period from July 1 to September 4. Five patients had discharge diagnoses of possible RMSF or fever with rash. Charts were reviewed on these five patients, and when possible they 
were interviewed. None were confirmed to have RMSF.The Sanford Hospital in adjoining Lee County reported that they routinely checked IFA titers on suspected cases and that no positive titers had been detected. A log was not available for review, but the head nurse did not remember any cases in which RMSF had been highly suspected.
GENERAL COMMUNITY SURVEY: In order to better define the community in which these cases were occurring, and to document possible additional RMSF cases, a survey was conducted at the church where one of the index case children had attended vacation Bible school two weeks before his illness. On Sunday September 6, 28 families filled out a household information questionnaire. Individual
fuestionnaires were competed on 61 persons in these families, erum was obtained for RMSF antibody testing on 54 persons.
ENVIRONMENTAL ASSESSMENT: Tick populations were assessed in several ways. Tick drags were attempted in three locations, but because the season of maximal tick activity was almost over no ticks were found. Alternative methods were employed.
1. Pet dogs of confirmed cases, possible cases, and selected community survey households were evaluated. Dogs nave previously been identified as potentially useful sentinel animals for human RMSF. Live ticks were pulled from 10 dogs and blood specimens for RMSF antibody testing were obtained on 20 dogs.
2. Small mammal trapping was done on three consecutive nights at three sites, and two nights at a fourth site. Three of these areas were homes or play areas of known cases and one was the home of a family who had been well. The following were obtained for blood testing and tick removal: 3 house mice, 7 field mice, 6 rats, 4 opossums, and 1 raccoon.
3. One deer carcass was examined, but no ticks were found.
FOLLOW-UP: Serologic testing should be complete by September 16. 
Data from cases, possible cases, and the community survey will be compiled and analyzed to compare with serologic results. A more complete report should be available by October 15, although final analysis of all data and animal specimens may take several months longer.
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USED FOB THE FOLLOWING PURPOSE:
DATE OF INVESTIGATION: B E G INN IN G :______________  E N D IN G :______________
Complete this section for each instrument used during the investigation
DATA COLLECTION METHOD
I—I I—I
I— I PERSONAL INTERVIEW '— 1 TELEPHONE
I—I I—I
I— I MAIL 1— 1 OTHER (pleas* specify):
A. DESCRIPTION OF RESPONDENTS (i.e.. individuals, households, physicians, state and local government, etc.)
B. ESTIMATED NUMBER OF RESPONDENTS:
C. NUMBER OF RESPONSES PER RESPONDENT (I.e., one time only, one* a week for 2 weeks, 6  times, etc.)
D. BURDEN PER RESPONSE (i.e., time »»ken for a respondent to complete the data oollection instrument)
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